The RTS,S vaccine candidate for malaria

Expert Review of Vaccines

Volumn 10, Issue 5, 2011, Pages 589-599

  Regules, Jason A ^a   Cummings, James F ^a   Ockenhouse, Christian F ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

adjuvant; falciparum; malaria; malaria vaccine; prime boost; RTS,S

Indexed keywords

ANTIGEN; MALARIA VACCINE; RTS,S; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; MALARIA; NONHUMAN; PRIORITY JOURNAL; REACTOGENICITY; SIDE EFFECT; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; HUMANS; MALARIA; MALARIA VACCINES; VACCINES;

EID: 79957590909     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.57     Document Type: Article

References (62)

1. WHO. Impact of Malaria Control. In: World Malaria Report 2010. WHO Press, Geneva, Switzerland, 39-62 (2010).
2. WHO. Impact of Malaria Control. In: World Malaria Report 2009. WHO Press, Geneva, Switzerland, 27-44 (2009).
3. Snow RW, Craig MH, Newton CR, Steketee RW. The public health burden of Plasmodium falciparum malaria in Africa. Working Paper 11. Disease Control Priorities Project, Bethesda, MD, USA (2003).
4. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216(5111), 160-162 (1967).
5. Clyde DF. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am. J. Trop. Med. Hyg. 24(3), 397-401 (1975).
6. Clyde DF, McCarthy VC, Miller RM, Hornick RB. Specificity of protection of man immunized against sporozoiteinduced falciparum malaria. Am. J. Med. Sci. 266(6), 398-403 (1973).
7. Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 207(4426), 71-73 (1980). (Pubitemid 10142301)
8. Potocnjak P, Yoshida N, Nussenzweig RS, Nussenzweig V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J. Exp. Med. 151(6), 1504 (1980).
9. Dame J, Williams J, McCutchan T et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225(4662), 593-599 (1984). (Pubitemid 14053761)
10. Rutgers T, Gordon D, Gathoye AM et al. Hepatitis B surface antigen as carrier matrix for the repetitive epitope of the circumsporozoite protein of Plasmodium falciparum. Nat. Biotech. 6(9), 1065-1070 (1988).
11. Vreden SGS, Verhave JP, Oettinger T, Sauerwein RW, Meuwissen J. Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen. Am. J. Trop. Med. Hyg. 45(5), 533 (1991).
12. Gordon DM, McGovern TW, Krzych U et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171(6), 1576-1585 (1995).
13. Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 336(2), 86 (1997).
14. Bojang KA, Milligan PJ, Pinder M et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358(9297), 1927-1934 (2001). (Pubitemid 34072872)
15. Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 21(1), 23-29 (2009).
16. Sun HX, Xie Y, Ye YP. Advances in saponin-based adjuvants. Vaccine 27(12), 1787-1796 (2009).
17. Kool M, Soullie T, van Nimwegen M et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205(4), 869-882 (2008). (Pubitemid 351549884)
18. Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 27(25-26), 3331-3334 (2009).
19. Fox CB, Friede M, Reed SG, Ireton GC. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell. Biochem. 53, 303-321 (2010).
20. Vandepapelière P, Horsmans Y, Moris P et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26(10), 1375-1386 (2008).
21. Rhee EG, Kelley RP, Agarwal I et al. TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector. J. Virol. 84(19), 10413-10419 (2010).
22. Alderson MR, McGowan P, Baldridge JR, Probst P. TLR4 agonists as immunomodulatory agents. J. Endotoxin Res. 12(5), 313-319 (2006). (Pubitemid 47471343)
23. Morefield GL, Hawkins LD, Ishizaka ST, Kissner TL, Ulrich RG. Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome. Clin. Vaccine Immunol. 14(11), 1499-1504 (2007). (Pubitemid 350304045)
24. Morel S, Didierlaurent A, Bourguignon P et al. Adjuvant System AS03 containing a-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29(13), 2461-2473 (2011).
25. Vogel FR, Caillet C, Kusters IC, Haensler J. Emulsion-based adjuvants for influenza vaccines. Expert Rev. Vaccines 8(4), 483-492 (2009).
26. Coler RN, Carter D, Friede M, Reed SG. Adjuvants for malaria vaccines. Parasite Immunol. 31(9), 520-528 (2009).
27. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6(5), 723-739 (2007). (Pubitemid 47607848)
28. Stoute JA, Kester KE, Krzych U et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. 178(4), 1139-1144 (1998). (Pubitemid 28452210)
29. Kester KE, McKinney DA, Tornieporth N et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis. 183(4), 640-647 (2001). (Pubitemid 32147521)
30. Kester KE, McKinney DA, Tornieporth N et al. A Phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults. Vaccine 25(29), 5359-5366 (2007). (Pubitemid 46977534)
31. Kester KE, Cummings JF, Ockenhouse CF et al. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 26(18), 2191-2202 (2008).
32. Sun P, Schwenk R, White K et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite proteinspecific CD4+ and CD8+ T cells producing IFN-g. J. Immunol. 171(12), 6961-6967 (2003). (Pubitemid 37532133)
33. Stewart V, Walsh DS, McGrath SM et al. Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques. Vaccine 24(42-43), 6493-6502 (2006). (Pubitemid 44511858)
34. Stewart V, McGrath SM, Walsh DS et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine 24(42-43), 6483-6492 (2006). (Pubitemid 44511857)
35. Mettens P, Dubois PM, Demoitié MA et al. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. Vaccine 26(8), 1072-1082 (2008).
36. Kester K, Cummings J, Ofori-Anyinam O et al. Randomized, double-blind, Phase 2a trial of falciparum malaria vaccines RTS,S/ AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200(3), 337-346 (2009).
37. Doherty JF, Pinder M, Tornieporth N et al. A Phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/ SBAS2 in semi-immune adults in The Gambia. Am. J. Trop. Med. Hyg. 61(6), 865-868 (1999). (Pubitemid 30084103)
38. Stoute JA, Heppner D Jr, Mason CJ et al. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of Western Kenya. Am. J. Trop. Med. Hyg. 75(1), 166-170 (2006). (Pubitemid 351627588)
39. Heppner DG, Cummings JF, Ockenhouse CF, Kester KE. New generation vaccines. In: New Generation Vaccines. Marcel Dekker, Inc., New York, NY, USA, 851-859 (2004).
40. Polhemus ME, Remich SA, Ogutu BR et al. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS ONE 4(7), e6465 (2009).
41. Bojang KA, Olodude F, Pinder M et al. Safety and immunogenicty of RTS,S/ AS02A candidate malaria vaccine in Gambian children. Vaccine 23(32), 4148-4157 (2005). (Pubitemid 40814590)
42. Macete E, Aponte JJ, Guinovart C et al. Safety and immunogenicity of the RTS,S/ AS02A candidate malaria vaccine in children aged 1-4 in Mozambique. Trop. Med. Int. Health 12(1), 37-46 (2007). (Pubitemid 44973852)
43. Alonso PL, Sacarlal J, Aponte JJ et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364(9443), 1411-1420 (2004). (Pubitemid 39370716)
44. Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366(9502), 2012-2018 (2005). (Pubitemid 41773376)
45. Guinovart C, Aponte JJ, Sacarlal J et al. Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a Phase IIb trial in Mozambican children. PLoS ONE 4(4), e5165 (2009).
46. Sacarlal J, Aide P, Aponte J et al. Long term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J. Infect. Dis. 200(3), 329-336 (2009).
47. Aponte JJ, Aide P, Renom M et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled Phase I/IIb trial. Lancet 370(9598), 1543-1551 (2007). (Pubitemid 350018877)
48. Abdulla S, Oberholzer R, Juma O et al. Safety and immunogenicity of RTS,S/ AS02D malaria vaccine in infants. N. Engl. J. Med. 359(24), 2533-2544 (2008).
49. Lell B, Agnandji S, von Glasenapp I et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS ONE 4(10), e7611 (2009).
50. Owusu-Agyei S, Ansong D, Asante K et al. Randomized controlled trial of RTS,S/ AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS ONE 4(10), e7302 (2009).
51. Bejon P, Lusingu J, Olotu A et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 359(24), 2521-2532 (2008).
52. Olotu A, Lusingu J, Leach A et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anticircumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect. Dis. 11(2), 102-109 (2011).
53. Agnandji ST, Asante KP, Lyimo J et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J. Infect. Dis. 202(7), 1076-1087 (2010).
54. Cummings J, Polhemus M, Kester K et al. Safety, immunogenicity, and efficacy of candidate malaria vaccine containing CSP and MSP-1 antigens. Presented at: 51st Annual Meeting of the American Society of Tropical Medicine and Hygiene. Denver, CO, USA, 10-14 November 2002.
55. Kester K, Heppner D, Ockenhouse C et al. Double-blind, randomized Phase I/IIa trial of SmithKline Beecham's candidate malaria vaccines RTS,S+TRAP and TRAP. Presented at: Molecular Approaches to Malaria. Erskine House, Lorne, Victoria, Australia(2000).
56. Pichyangkul S, Kum-Arb U, Yongvanitchit K et al. Peclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates. Infect. Immun. 76(1), 229-238 (2007).
57. Epstein JE, Charoenvit Y, Kester KE et al. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/ AS02A. Vaccine 22(13-14), 1592-1603 (2004). (Pubitemid 38447205)
58. Wang R, Epstein J, Charoenvit Y et al. Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. J. Immunol. 172(9), 5561-5569 (2004). (Pubitemid 38542058)
59. Dunachie SJ, Walther M, Vuola JM et al. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/ AS02A and MVA-CS. Vaccine 24(15), 2850-2859 (2006).
60. Stewart VA, McGrath SM, Dubois PM et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect. Immun. 75(5), 2283-2290 (2007). (Pubitemid 46744316)
61. Rodríguez A, Mintardjo R, Tax D et al. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys. Vaccine 27(44), 6226-6233 (2009).
62. Draper SJ, Biswas S, Spencer AJ et al. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J. Immunol. 185(12), 7583-7595 (2010).